Neuroscience & CNS
Part of Biotech - Drug Development
 BIIB | Biogen Inc. Common Stock | $31.9b | $205.05 | -1.4% | 892.7K |
 NBIX | Neurocrine Biosciences Inc | $16.9b | $171.60 | -0.5% | 645.4K |
 JAZZ | Jazz Pharmaceuticals, Inc. | $15.1b | $248.12 | +2.2% | 390.2K |
 AXSM | Axsome Therapeutics, Inc | $12.6b | $229.90 | -3.0% | 665.5K |
 CYTK | Cytokinetics Inc. | $11.6b | $80.80 | -0.3% | 1.4M |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | $9.3b | $314.74 | +1.9% | 242.8K |
 ALKS | Alkermes Inc. plc | $8.7b | $52.70 | +1.5% | 962.2K |
 TGTX | TG Therapeutics, Inc. | $8.4b | $55.43 | -0.1% | 1.3M |
 PTCT | PTC Therapeutics, Inc. | $6.8b | $78.56 | 0.0% | 537.1K |
 DFTX | Definium Therapeutics, Inc. Common Shares | $6.2b | $44.20 | +0.3% | 1.3M |
 XENE | Xenon Pharmaceuticals Inc | $5.8b | $69.22 | +1.9% | 1.1M |
 INDV | Indivior Pharmaceuticals, Inc. Common Stock | $4.8b | $40.67 | -0.1% | 770.1K |
 ACAD | Acadia Pharmaceuticals Inc. | $4.3b | $25.55 | -0.1% | 900.0K |
 DNLI | Denali Therapeutics Inc. Common Stock | $4.1b | $23.71 | +2.4% | 1.3M |
 ALMS | Alumis Inc. Common Stock | $3.6b | $28.68 | +5.5% | 867.0K |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | $3.0b | $4.99 | +5.1% | 142.5K |
 SUPN | Supernus Pharmaceuticals, Inc. | $2.7b | $48.05 | -0.3% | 338.4K |
 BHVN | Biohaven Ltd. | $2.2b | $15.39 | +9.0% | 3.2M |
 HRMY | Harmony Biosciences Holdings, Inc. Common Stock | $2.1b | $33.77 | +0.6% | 564.7K |
 STOK | Stoke Therapeutics, Inc. Common Stock | $2.0b | $29.08 | -0.3% | 313.3K |
 AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | $2.0b | $17.74 | +4.2% | 1.1M |
 RAPP | Rapport Therapeutics, Inc. Common Stock | $2.0b | $42.50 | +6.0% | 406.3K |
 TSHA | Taysha Gene Therapies, Inc. Common Stock | $2.0b | $6.12 | -0.3% | 2.4M |
 ATAI | AtaiBeckley Inc. Common Stock | $1.9b | $7.15 | +0.8% | 40.1M |
 GHRS | GH Research PLC Ordinary Shares | $1.8b | $28.66 | -1.2% | 591.7K |
 MPLT | MapLight Therapeutics, Inc. Common Stock | $1.6b | $37.70 | +2.0% | 726.5K |
 COLL | Collegium Pharmaceutical, Inc. Common Stock | $1.2b | $36.09 | -0.5% | 235.1K |
 ANNX | Annexon, Inc. Common Stock | $0.9b | $5.94 | -1.9% | 3.0M |
 LBRX | LB Pharmaceuticals Inc Common Stock | $0.9b | $31.54 | +2.7% | 130.3K |
 ANRO | Alto Neuroscience Inc. | $0.9b | $27.53 | +0.8% | 692.8K |
 TBPH | Theravance Biopharma, Inc. | $0.9b | $16.93 | -0.2% | 330.9K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.7b | $5.48 | -4.3% | 3.1M |
 DRUG | Bright Minds Biosciences Inc. Common Stock | $0.7b | $76.07 | +4.5% | 150.9K |
 CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $0.6b | $14.25 | +2.0% | 120.2K |
 AQST | Aquestive Therapeutics, Inc. Common Stock | $0.5b | $4.12 | +4.7% | 2.2M |
 PRTA | Prothena Corporation plc Ordinary Shares | $0.5b | $8.60 | +2.1% | 328.9K |
 OVID | Ovid Therapeutics Inc. Common Stock | $0.5b | $2.50 | -0.8% | 926.4K |
 HELP | Cybin Inc. Common Stock | $409.8m | $7.23 | +3.0% | 3.0M |
 VNDA | Vanda Pharmaceuticals Inc. | $368.0m | $5.44 | 0.0% | 759.3K |
 NMRA | Neumora Therapeutics, Inc. Common Stock | $315.0m | $1.55 | 0.0% | 923.7K |
 ELDN | Eledon Pharmaceuticals, Inc. Common Stock | $304.1m | $4.00 | +6.1% | 689.1K |
 IKT | Inhibikase Therapeutics, Inc. Common Stock | $268.0m | $2.09 | +5.0% | 1.6M |
 NERV | Minerva Neurosciences, Inc | $258.6m | $4.26 | +1.4% | 156.3K |
 ACIU | AC Immune SA | $242.2m | $2.25 | +0.5% | 343.9K |
 AVXL | Anavex Life Sciences | $240.0m | $2.43 | +2.1% | 1.8M |
 ALEC | Alector, Inc. Common Stock | $223.2m | $1.50 | +2.7% | 396.4K |
 NGEN | NervGen Pharma Corp. Common stock | $218.8m | $1.67 | -0.3% | 850.0K |
 VYGR | Voyager Therapeutics, Inc. Common Stock | $211.5m | $3.08 | +4.3% | 864.7K |
 TNXP | Tonix Pharmaceuticals Holding Corp. | $203.4m | $12.38 | +4.4% | 669.5K |
 ABOS | Acumen Pharmaceuticals, Inc. Common Stock | $192.8m | $2.18 | +3.7% | 265.3K |